Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586880 | 0.73 | NAAA (0.37) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL6285824 | 0.70 | RAB9A (0.39) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL4585682 | 0.66 | GAA (0.43) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL13387564 | 0.65 | GAA (0.59) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL4719490 | 0.65 | GAA (0.59) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL12510922 | 0.64 | GAA (0.51) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL4586040 | 0.63 | GAA (0.42) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL16145654 | 0.63 | GAA (0.49) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL12640895 | 0.63 | GAA (0.49) | NAAASMN1; SMN2MAPK1GAAHTT | |
| SCHEMBL1827279 | 0.63 | EPHX1 (0.64) | SMN1; SMN2MAPK1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962907-B2 | Neurologically-active compounds | THE UNIVERSITY OF SYDNEY (AU) | 2005-11-08 | — | — | US | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | NAAA 686/4885SMN1; SMN2 250/4885MAPK1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.